Myria Biosciences
Myria Biosciences is revolutionizing drug discovery by integrating synthetic biology, artificial intelligence, and super-speed analytics to create AI-designed microbes that produce novel therapeutic compounds. Their GEMMS (Genetically Engineered Modular Molecule Scaffolds) platform enables the design and biological production of chemical compounds beyond natural evolution, aiming to unlock new chemical space for challenging disease targets. The company focuses on generating and optimizing targeted biopharmaceuticals for unmet medical needs at unprecedented speed and precision.
Myria Biosciences
Myria Biosciences is revolutionizing drug discovery by integrating synthetic biology, artificial intelligence, and super-speed analytics to create AI-designed microbes that produce novel therapeutic compounds. Their GEMMS (Genetically Engineered Modular Molecule Scaffolds) platform enables the design and biological production of chemical compounds beyond natural evolution, aiming to unlock new chemical space for challenging disease targets. The company focuses on generating and optimizing targeted biopharmaceuticals for unmet medical needs at unprecedented speed and precision.
TL;DR
What they do: Use synthetic biology + AI (GEMMS platform) to design microbes that produce novel therapeutic compounds
HQ: Basel, Switzerland
Founded: 2022
Stage / funding: Pre-seed (closed June 2024) with named investors including Creator Fund
Team size: About 10 employees (reported)
Company Overview
Problem Domain
Drug discovery for unmet medical needs; accessing novel chemical space using engineered biology
Founded
2022
Industry
Biotechnology
Tech Stack
Funding Track Record
Pre-seed round announced as closed on company site (20 June 2024); investor participants include Creator Fund (lead), Capital Blue Partners, Rockmount Seed Investments.
Investor Signal
“Led by Creator Fund with participation from Capital Blue Partners and Rockmount Seed Investments”